JP2009505960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009505960A5 JP2009505960A5 JP2008524052A JP2008524052A JP2009505960A5 JP 2009505960 A5 JP2009505960 A5 JP 2009505960A5 JP 2008524052 A JP2008524052 A JP 2008524052A JP 2008524052 A JP2008524052 A JP 2008524052A JP 2009505960 A5 JP2009505960 A5 JP 2009505960A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- optionally
- alkyl
- substituted
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 74
- 150000001875 compounds Chemical class 0.000 claims 62
- 125000000623 heterocyclic group Chemical group 0.000 claims 60
- 125000003710 aryl alkyl group Chemical group 0.000 claims 54
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 53
- -1 cyano, nitro, guanidino Chemical group 0.000 claims 52
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 52
- 125000000547 substituted alkyl group Chemical group 0.000 claims 52
- 125000001475 halogen functional group Chemical group 0.000 claims 51
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 239000000651 prodrug Substances 0.000 claims 46
- 229940002612 prodrug Drugs 0.000 claims 46
- 150000003839 salts Chemical class 0.000 claims 46
- 239000012453 solvate Substances 0.000 claims 46
- 125000003107 substituted aryl group Chemical group 0.000 claims 44
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 43
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 42
- 125000000304 alkynyl group Chemical group 0.000 claims 39
- 125000004438 haloalkoxy group Chemical group 0.000 claims 37
- 125000001188 haloalkyl group Chemical group 0.000 claims 37
- 125000004404 heteroalkyl group Chemical group 0.000 claims 35
- 125000001424 substituent group Chemical group 0.000 claims 35
- 125000003545 alkoxy group Chemical group 0.000 claims 29
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000003342 alkenyl group Chemical group 0.000 claims 20
- 125000003282 alkyl amino group Chemical group 0.000 claims 18
- 125000004663 dialkyl amino group Chemical group 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000005907 alkyl ester group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 229920003169 water-soluble polymer Polymers 0.000 claims 8
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims 6
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 235000004554 glutamine Nutrition 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000014304 histidine Nutrition 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 0 CC(*)c1cc(*)c(*)c(*)c1 Chemical compound CC(*)c1cc(*)c(*)c(*)c1 0.000 description 8
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70223705P | 2005-07-25 | 2005-07-25 | |
| US60/702,237 | 2005-07-25 | ||
| US74941805P | 2005-12-12 | 2005-12-12 | |
| US60/749,418 | 2005-12-12 | ||
| US78048806P | 2006-03-08 | 2006-03-08 | |
| US60/780,488 | 2006-03-08 | ||
| PCT/US2006/028801 WO2007014198A1 (en) | 2005-07-25 | 2006-07-24 | 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009505960A JP2009505960A (ja) | 2009-02-12 |
| JP2009505960A5 true JP2009505960A5 (enExample) | 2009-09-10 |
| JP5149177B2 JP5149177B2 (ja) | 2013-02-20 |
Family
ID=37478877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524052A Expired - Fee Related JP5149177B2 (ja) | 2005-07-25 | 2006-07-24 | 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US7781462B2 (enExample) |
| EP (1) | EP1919881B1 (enExample) |
| JP (1) | JP5149177B2 (enExample) |
| AU (1) | AU2006272652B2 (enExample) |
| CA (1) | CA2614919C (enExample) |
| ES (1) | ES2408597T3 (enExample) |
| TW (1) | TWI462908B (enExample) |
| WO (1) | WO2007014198A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2408597T3 (es) * | 2005-07-25 | 2013-06-21 | Synta Pharmaceuticals Corporation | 1,2,3-triazoles inhibidores de la polimerización de la tubulina para el tratamiento de trastornos proliferativos |
| AU2008287367B2 (en) * | 2007-08-13 | 2012-02-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| CN103003264B (zh) | 2010-05-21 | 2014-08-06 | 切米利亚股份公司 | 嘧啶衍生物 |
| HUE025697T2 (en) * | 2010-12-20 | 2016-04-28 | Sigma-Tau Res Switzerland S A | Aryl triazole compounds having antitumor activity |
| EP2502924A1 (en) | 2011-03-24 | 2012-09-26 | Chemilia AB | Novel pyrimidine derivatives |
| AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
| US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| CA2854188A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| EP2711365A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| US9597316B2 (en) | 2012-12-28 | 2017-03-21 | Bioventures Llc | Indole compounds for use in treating inflammation and cancer |
| SG11201508054UA (en) | 2013-04-19 | 2015-11-27 | Univ Arkansas | Combretastatin analogs |
| WO2015153635A1 (en) | 2014-03-31 | 2015-10-08 | Board Of Trustees Of The University Of Arkansas | Disubstituted triazole analogs |
| EP2944635B1 (en) * | 2014-05-15 | 2018-11-28 | Council of Scientific & Industrial Research | Pyrazole linked benzimidazole conjugates and a process for preparation thereof |
| AU2017258304B2 (en) | 2016-04-27 | 2019-07-04 | University Of Puerto Rico | 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases |
| CN109456312B (zh) * | 2018-10-29 | 2021-06-04 | 郑州大学 | 1,2,3-三氮唑类微管蛋白聚合抑制剂其合成方法和应用 |
| US11894884B2 (en) | 2019-09-25 | 2024-02-06 | Alarm.Com Incorporated | Modular electrical grid communications platform |
| US20250214973A1 (en) * | 2022-05-20 | 2025-07-03 | University Of Puerto Rico | 1,4,5-trisubstituted-1,2,3-triazoles and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| JP2004532234A (ja) * | 2001-04-27 | 2004-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | トリアゾール由来キナーゼインヒビターおよびその使用 |
| UA79286C2 (en) | 2002-06-29 | 2007-06-11 | Zentaris Gmbh | Arylcarbonylpipererazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumors |
| AU2003260810A1 (en) * | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| ITRM20030355A1 (it) * | 2003-07-18 | 2005-01-19 | Sigma Tau Ind Farmaceuti | Composti ad attivita' citotossica derivati della combretastatina. |
| ES2408597T3 (es) | 2005-07-25 | 2013-06-21 | Synta Pharmaceuticals Corporation | 1,2,3-triazoles inhibidores de la polimerización de la tubulina para el tratamiento de trastornos proliferativos |
-
2006
- 2006-07-24 ES ES06788396T patent/ES2408597T3/es active Active
- 2006-07-24 EP EP06788396.7A patent/EP1919881B1/en active Active
- 2006-07-24 CA CA2614919A patent/CA2614919C/en not_active Expired - Fee Related
- 2006-07-24 US US11/492,692 patent/US7781462B2/en not_active Expired - Fee Related
- 2006-07-24 WO PCT/US2006/028801 patent/WO2007014198A1/en not_active Ceased
- 2006-07-24 AU AU2006272652A patent/AU2006272652B2/en not_active Ceased
- 2006-07-24 JP JP2008524052A patent/JP5149177B2/ja not_active Expired - Fee Related
- 2006-07-25 TW TW095127101A patent/TWI462908B/zh not_active IP Right Cessation
-
2010
- 2010-04-27 US US12/768,164 patent/US20100279410A1/en not_active Abandoned
-
2011
- 2011-10-04 US US13/252,423 patent/US8501790B2/en not_active Expired - Fee Related
-
2013
- 2013-08-01 US US13/956,534 patent/US9175022B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009505960A5 (enExample) | ||
| JP2010031025A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| AR070522A1 (es) | Derivados de pirido 4,3-d-pirimidinona como inhibidores de cinasa, una composicion farmaceutica y un metodo para el tratamient0 de una enfermedad, un medicamento en base al compuesto y el uso de este para la fabricacion de un medicamento | |
| JP2008525416A5 (enExample) | ||
| JP2016529324A5 (enExample) | ||
| JP2007511527A5 (enExample) | ||
| AR072688A1 (es) | Nucleosidos y nucleotidos biciclicos como agentes terapeuticos | |
| JP2019537599A5 (enExample) | ||
| JP2010527913A5 (enExample) | ||
| CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
| JP2015532295A5 (enExample) | ||
| JP2012513409A5 (enExample) | ||
| PE20090216A1 (es) | Compuestos triazolil aminopirimidina | |
| JPWO2020086739A5 (enExample) | ||
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| JP2009500424A5 (enExample) | ||
| JP2013500304A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2007511535A5 (enExample) | ||
| RU2013130256A (ru) | Новые циклоспориновые производные для лечения и предупреждения вирусных инфекций | |
| EA200970572A1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| JP2010501478A5 (enExample) |